Principal Scientist
Merck & Co., Inc.
Ambler, Pennsylvania
Melanie Anderson is a principal scientist at Merck, Sharp, and Dohme (NJ, USA) with over 20 years’ experience in bioanalysis for small and large molecules and vaccines. In her current role, she is responsible for modernizing vaccine assays for licensed vaccines. Melanie has worked on patient centric sampling approaches for both biomarkers and PK applications. She recently co-led a cross-functional team at Merck working to operationalize patient centric sampling technology. She currently co-chairs the PCSIG working group on diagnostics and co-chaired the CPLG/TALG IQ Patient Centric Sampling Group (sunset 2023) which published an editorial entitled “Will pateint-centric sampling become the norm for clinical trials after COVID-19?” in Nature Medicine in November 2020. She received her BA in Chemistry from Hasting College (NE, USA), and an MS in Chemistry from Lehigh University (PA, USA).
Disclosure information not submitted.